Avid Bioservices (CDMO) Reports Q3 Loss of $0.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2019 and Recent Developments
March 11, 2019 4:05 PM EDT-- Achieved Revenue of $13.8 Million, an Increase of 102%Compared to Prior Year Quarter --
-- Signed Project Expansion Orders with Existing Customers Representing $23.8 Million --
-- Completed Process Validation Campaign for Future Commercial Production with Other Validations Ongoing --
TUSTIN, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and... More
